AI Article Synopsis
Article Abstract
A random sample of 500 cases from a total 5611 cases collected from a survey of melanoma in New South Wales, Australia, has confirmed an incidence rise which is apparent across all degrees of severity and all histogenetic classes. It therefore can be stated that the apparent increasing incidence of melanoma in New South Wales is not due to diagnostic errors. Nor is it due to inadequate registration of early melanomas in the initial years of study. The present study concludes that the increased rate of reporting of melanoma by New South Wales pathology services represents a true rise in the incidence of melanoma in the State.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pulsed electric field (PEF) treatment of refractory vulvar melanoma concurrently treated with immune checkpoint blockade demonstrating an abscopal response: A case report.
Gynecol Oncol Rep
February 2025
Prisma Health Cancer Institute, Greenville, SC 29605, USA.
•Vulvar melanoma is deadlier and harder to treat than typical melanoma.•82-year-old female had metastatic vulvar melanoma that reoccurred on immunotherapy.•Treatment with pulsed electric field therapy led to rapid resolution of metastatic disease.
View Article and Find Full Text PDFPan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
J Immunother Cancer
January 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Background: Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To interrogate mechanisms of divergent immune responses in obese and non-obese patients, we examined the relationship among obesity status, clinical responses, and immune profiles from a diverse, pan-tumor cohort of patients treated with ICI-based therapy.
Methods: From June 2021 to March 2023, we prospectively collected serial peripheral blood samples from patients with advanced or metastatic solid tumors who received ICI as standard of care at Johns Hopkins.
A Review of Current Treatment Options for Stage III and Stage IV Metastatic Melanoma.
S D Med
October 2024
Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
The incidence of melanoma has increased for decades, and while surgical treatment of early stage disease is often curative, metastatic disease continues to have significant morbidity and mortality and carries a high associated health burden and economic cost. An expanding number of dermatologists are playing a key role in coordinating the care of patients with advanced melanoma, including in the setting of multidisciplinary melanoma clinics, many of which are anchored in dermatology departments. Advances in the understanding of the genetic and immunoregulatory aspects of melanoma development and progression have yielded a wave of novel therapeutics that has made significant impact on the approach to patients with metastatic disease.
View Article and Find Full Text PDFEndothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity.
J Clin Invest
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Stimulator of interferon genes (STING) agonists have been developed and tested in clinical trials for their antitumor activity. However, the specific cell population(s) responsible for such STING activation-induced antitumor immunity have not been completely understood. In this study, we demonstrated that endothelial STING expression was critical for STING agonist-induced antitumor activity.
View Article and Find Full Text PDFEngineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.
Sci Adv
January 2025
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from natural killer cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!